Pharmaceutical

SOR-007 by Nanology for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

SOR-007 is under clinical development by Nanology and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas.

Dec 22, 2023 - 18:00
SOR-007 is under clinical development by Nanology and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas.
Read the original article

Tags:

Previous Article

Cadonilimab by Akeso for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood o...

Next Article

Jazz Pharmaceuticals Faces Setback in JZP150 Phase II Trial for PTSD Treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Merck to acquire Prometheus Biosciences, maker of autoimmune drugs, for $10.8 billion

STAT+: Merck to acquire Prometheus Biosciences, maker o...

Apr 17, 2023

AstraZeneca posts $2.18bn profit after tax in Q1 2024

AstraZeneca posts $2.18bn profit after tax in Q1 2024

Apr 27, 2024

STAT+: Demand spikes in seniors, behavioral health care challenge UnitedHealth’s provider arm

STAT+: Demand spikes in seniors, behavioral health care...

Jul 14, 2023